Bovine Tuberculosis Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tests (Molecular Diagnostic Tests, Serological Tests, Traditional Tests), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 782.12 MIllion
CAGR (2026-2031)	5.27%
Fastest Growing Segment	Traditional Tests
Largest Market	Europe
Market Size (2031)	USD 1064.39 MIllion

Market Overview

The Global Bovine Tuberculosis Diagnosis Market will grow from USD 782.12 MIllion in 2025 to USD 1064.39 MIllion by 2031 at a 5.27% CAGR. Bovine tuberculosis diagnosis encompasses the veterinary protocols and assays, such as tuberculin skin tests and gamma-interferon detection, utilized to identify Mycobacterium bovis infection in cattle. The market is primarily supported by stringent government-mandated eradication programs designed to mitigate zoonotic risks and ensure compliance with international trade regulations that require disease-free certification for livestock exports. These regulatory drivers compel the continuous testing of herds to prevent economic losses associated with widespread outbreaks.

However, the market faces a significant impediment regarding the persistence of infection reservoirs in wildlife, which complicates eradication efforts and necessitates repeated, costly screening. This difficulty is underscored by recent data highlighting the severity of the issue despite control measures. According to NFU Cymru, in 2025, over 13,000 cattle were slaughtered in Wales during 2024 due to bovine tuberculosis, marking a 27% increase from the previous year. Such statistics illustrate the ongoing challenge of disease management which can strain resources and limit broader market efficiency.

Key Market Drivers

The implementation of mandatory government eradication and surveillance programs constitutes the primary catalyst for market growth, as regulatory bodies enforce strict testing protocols. These initiatives compel regular herd screening, ensuring consistent demand for diagnostic consumables. The scale of this intervention is evident in the testing volumes required for compliance. For instance, according to the Department for Environment, Food & Rural Affairs, in 2025, over 7.2 million cattle tests were conducted in England. This effort is underpinned by significant public funding. According to the Department of Agriculture, Food and the Marine, October 2025, in the 'Quarter 3 2025 Bovine TB Disease Trends and Expenditure' report, government expenditure on the bovine TB eradication programme in Ireland reached €79.4 million by the third quarter, a 20% increase year-on-year.

Technological advancements in molecular and rapid diagnostic assays are reshaping the market by addressing the limitations of traditional methods. Innovations like the Detect Infected among Vaccinated Animals (DIVA) skin test are critical, enabling the differentiation between infected and vaccinated cattle. These advanced diagnostics are moving rapidly from research to practical application. According to the Animal and Plant Health Agency, October 2025, in the 'Cattle Vaccine Project' announcement, Phase 3 field trials for the companion DIVA skin test were launched, involving the testing of at least 750 animals. Such advancements enhance diagnostic accuracy and support the strategic goal of total eradication, ensuring the market evolves toward higher-precision testing solutions.

Download Free Sample Report

Key Market Challenges

The persistence of infection reservoirs in wildlife populations constitutes a substantial impediment to the Global Bovine Tuberculosis Diagnosis Market. This biological factor creates a continuous cycle of re-infection where cattle herds, even after undergoing rigorous testing and clearance, remain vulnerable to re-contamination from local wildlife vectors such as badgers or deer. This constant threat undermines the effectiveness of standard test-and-slaughter protocols, forcing the industry to focus heavily on reactive crisis management rather than proactive market development. The unpredictability of these wildlife-driven outbreaks strains the financial resources of the livestock sector, limiting the capital available for the adoption of comprehensive diagnostic testing regimes.

This economic pressure is clearly evidenced by recent industry data which underscores the severity of the situation. According to the Ulster Farmers' Union, in 2024, the annual herd incidence rate of bovine tuberculosis in Northern Ireland rose to over 10.4 percent, driven largely by wildlife transmission dynamics. Such elevated incidence rates illustrate how the inability to control wildlife reservoirs perpetuates the disease, thereby creating a volatile market environment that hampers steady growth and reduces the overall efficiency of global diagnostic strategies.

Key Market Trends

The Expansion of Wildlife Reservoir Surveillance and Monitoring represents a pivotal shift in diagnostic focus, moving beyond cattle-centric protocols to address the persistence of infection in environmental vectors. Veterinary authorities are increasingly deploying forensic testing on wildlife populations, such as badgers, to map disease transmission pathways and evaluate the efficacy of vaccination interventions. This active monitoring creates a specialized market niche for post-mortem diagnostic kits and rapid field sampling tools designed for non-bovine species, enabling more targeted biosecurity strategies. According to the Irish Farmers Journal, May 2025, in the 'Over 20% of badgers test positive for TB' report, the Department of Agriculture, Environment and Rural Affairs (DAERA) collected and tested 465 badger carcasses in Northern Ireland during 2024 as part of an intensified roadside surveillance project to monitor disease reservoirs.

The Transition from Tuberculin Skin Tests to Molecular Diagnostic Assays is simultaneously revolutionizing the speed and accuracy of disease confirmation. Laboratories are progressively replacing slow bacterial cultures with polymerase chain reaction (PCR) and Whole Genome Sequencing (WGS), which provide rapid identification of Mycobacterium bovis strains and facilitate precise epidemiological tracing. This technological evolution significantly reduces the time herds remain under movement restrictions and supports strategic eradication by identifying local infection clusters with genomic precision. According to the Animal and Plant Health Agency, September 2025, in the 'Bovine tuberculosis in England in 2024' report, Whole Genome Sequencing (WGS) analysis was successfully completed for 888 new herd incidents where officially TB-free status was withdrawn, underscoring the integration of advanced genomics into routine disease management.

Segmental Insights

Based on recent market intelligence, the Traditional Tests segment is emerging as the fastest growing category in the Global Bovine Tuberculosis Diagnosis Market. This rapid expansion is primarily driven by the intensifying enforcement of government-led eradication programs in developing economies, where cost-efficiency is paramount for mass screening. Regulatory bodies frequently mandate the Single Intradermal Comparative Cervical Tuberculin test as the standard primary protocol for international trade compliance and herd certification. Consequently, the established infrastructure and scalability of these diagnostics ensure their accelerated adoption for large-scale surveillance compared to higher-cost alternatives.

Regional Insights

Europe maintains a leading position in the Global Bovine Tuberculosis Diagnosis Market, driven by rigorous regulatory frameworks and comprehensive eradication initiatives. The region’s commitment to disease control is enforced through strict surveillance protocols, such as the European Union’s Animal Health Law, which mandates regular testing to ensure herd health and food safety. Countries like the United Kingdom, guided by the Department for Environment, Food & Rural Affairs (DEFRA), implement intensive screening programs that sustain high market demand. Furthermore, the widespread adoption of accurate molecular diagnostic technologies facilitates early detection, ensuring compliance with international trade standards and minimizing economic losses for livestock producers.

Recent Developments

• In July 2025, PBD Biotech launched a new lyophilised qPCR Kit for the detection of the Mycobacterium tuberculosis Complex (MTBC). The company announced that the new product was designed to provide rapid and reliable detection of the pathogen in both animals and humans, offering high sensitivity and specificity across a wide range of sample types. PBD Biotech highlighted that the assay was ready-to-use and did not require a cold chain for transport, making it particularly suitable for use in field settings and low-resource environments to support improved surveillance of tuberculosis.
• In May 2025, Zoetis opened a new reference laboratory in Louisville, Kentucky, which was co-located with a logistics hub to accelerate sample turnaround times nationwide. This facility was established to enhance the company's diagnostic services, including those for livestock diseases. Industry reports indicated that the expansion was part of a broader strategy to support the bovine tuberculosis diagnosis market by providing faster confirmation and complex analytics for veterinary professionals and producers, thereby facilitating more efficient disease management and control programs.
• In February 2025, the UK’s Animal and Plant Health Agency (APHA) announced the commencement of the third phase of field trials for a cattle BCG vaccine and a companion Detect Infected among Vaccinated Animals (DIVA) skin test. The pilot batches of the DIVA skin test were supplied by Lionex, a company specializing in mycobacterial antigens for diagnostics. This phase of the trial was conducted on commercial livestock farms and aimed to gather essential data on the test's specificity to support future marketing authorization applications, marking a significant step toward a deployable vaccination and diagnostic strategy for bovine tuberculosis.
• In April 2024, researchers from Enfer Scientific, in collaboration with academic and veterinary partners, published a study validating the performance of the Enferplex Bovine TB antibody test using individual milk samples. The research, published in PLoS ONE, demonstrated that the serological test achieved a diagnostic specificity of 99.7% and a relative sensitivity of 90.8% in boosted samples from skin test-positive animals. The study concluded that milk samples could serve as a viable medium for the diagnosis of bovine tuberculosis, offering a highly accurate and potential alternative to serum-based testing for dairy herds.

Key Market Players

• IDEXX Laboratories, Inc.
• PBD Biotech Ltd
• Zoetis Inc.
• Innovative Diagnostics SAS
• Thermo Fisher Scientific Inc.
• Enfer Group
• AsureQuality Australia Pty Ltd.
• Bio-Rad Laboratories, Inc.
• Bionote USA Inc.
• Neogen Corporation

By Tests	By Region
Molecular Diagnostic Tests Serological Tests Traditional Tests	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Bovine Tuberculosis Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Bovine Tuberculosis Diagnosis Market, By Tests:

• Molecular Diagnostic Tests
• Serological Tests
• Traditional Tests

• Bovine Tuberculosis Diagnosis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE